“`html
Albemarle Corporation (ALB) is facing significant volatility in its stock performance, with shares declining by -14.4% over the past month, contrasting with a +4.1% gain in the S&P 500. The Zacks Chemical – Diversified industry has also experienced a -6.3% change during the same period. Current earnings estimates for the upcoming quarter stand at $0.74 per share, reflecting a -89.9% year-over-year decline, while the fiscal year estimate has dipped -90.7% to $2.07.
Last reported revenues were $1.36 billion, down -47.3% year-over-year, and missed the consensus estimate by +3.91%. For the next fiscal year, earnings estimates are projected to recover to $5.61, a 170.9% increase from prior expectations. The company holds a Zacks Rank of #3 (Hold), signaling a performance in line with the broader market.
The consensus sales estimate for the current quarter is $1.41 billion, indicating a decrease of -40.5%. By the next fiscal year, revenue forecasts suggest growth to $6.72 billion, an increase of 15.3%. As an investment consideration, Albemarle is currently rated C on the Zacks Value Style Score, indicating it is trading at par with its peers.
“`
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
